CA-ALVEO-TECHNOLOGIES
17.11.2022 15:46:40 CET | Business Wire | Press release
Alveo Technologies, Inc. (Alveo) today announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™. The company, seeking to catalyze broader adoption of its highly differentiated platform, is actively seeking collaborators to rapidly expand the menu of assays available within healthcare and beyond.
The innovative be.well™ platform, a prior X-Prize winner, pairs advanced molecular assays with secure, HIPAA- and GDPR-compliant cloud-enabled data analytics for real-time disease, pathogen and contaminant diagnoses, detection, and analysis. Designed to bring molecular sensing and diagnostics closer to the point of need, whether at the point of care, over the counter, at home, or in the field, the rapid, handheld and portable be.well™ platform can be customized to detect a wide range of diseases including COVID-19, Influenza A/B, and RSV, sexually transmitted infections and urinary tract infections as well as applications for veterinary, agricultural, and other industrial markets where low cost, accurate, rapid molecular testing, sampling, or detection capabilities are needed.
New Executive Leadership to Ensure Universal Access to Groundbreaking Technology
Shaun Holt, Chief Executive Officer, and Chairman of the Board of Directors
Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.
Erik Tyrrell-Knott, Chief Business and Strategy Officer
As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.
Slava Elagin, PhD, MBA, Chief Technology Officer
Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industries. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.
Proprietary Advanced Molecular Sensing Technology Offers Distinct Advantages
Alveo is leading the transformation of the point-of-need molecular sensing and health tech markets with an “open platform” approach to co-developing rapid molecular testing capabilities with collaborative partners across multiple markets.
“Alveo has spent seven years and more than $70 million dollars developing a bulletproof, mobile “Molecular Lab” that can deliver exquisitely sensitive and specific testing wherever, whenever it is needed: literally in the field for crop testing, on farms for animal testing, and most importantly in labs, pharmacies, and doctors’ offices for various infectious diseases,” says CEO Shaun Holt. “The future of healthcare, and molecular sensors as a whole, lies closer and closer to the patient or point of need, and the multiplexed Alveo platform will deliver insight and guidance with zero compromise.”
The be.well™ platform is the only point-of-care diagnostic platform available today that utilizes Alveo’s proprietary and globally patented method for the direct electrical sensing of nucleic acid amplification. This technology eliminates the need for specialized lighting and expensive optical detectors, while also simplifying certain aspects of primer manufacturing, providing a more robust and reliable diagnostic instrument.
Alveo’s platform can be used with various specimen types, such as nasal, blood, or urine samples, which eliminates the need to modify the platform design for different disease applications. The design architecture -- with a total of 15 components -- is reusable and rechargeable, Bluetooth- and cloud-enabled, with no moving parts or hazardous waste, is environmentally friendly, reduces manufacturing costs and limits supply chain risk. The simplicity of the detection methodology, its lower cost compared to other single-use diagnostic tests, and its wide range of health and disease applications are key advantages driving Alveo’s commercialization partnerships.
“A seminal pillar of Alveo’s growth is to open our platform to companies with expertise, market reach, and customer insights that extend beyond what Alveo can accomplish on our own,” says Erik Tyrrell-Knott. “Collaborating with partners to take molecular testing out of the lab, into new markets, and deliver actionable insights at the point of need is our core focus. The doors are open, and we are ready to co-develop.”
Alveo’s be.well™ COVID-19 Test received CE (Conformité Européene) Mark regulatory approval and the company is initially scaling up production for commercialization in the United Kingdom and European Union. Alveo is also actively pursuing 510(K) clearance from the U.S. Food and Drug Administration.
About Alveo
At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.
To learn more, visit https://alveotechnologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005419/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
